IL148456A0 - Combined vaccine compositions - Google Patents

Combined vaccine compositions

Info

Publication number
IL148456A0
IL148456A0 IL14845600A IL14845600A IL148456A0 IL 148456 A0 IL148456 A0 IL 148456A0 IL 14845600 A IL14845600 A IL 14845600A IL 14845600 A IL14845600 A IL 14845600A IL 148456 A0 IL148456 A0 IL 148456A0
Authority
IL
Israel
Prior art keywords
vaccine compositions
combined vaccine
combined
compositions
vaccine
Prior art date
Application number
IL14845600A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL148456A0 publication Critical patent/IL148456A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
    • E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental & Geological Engineering (AREA)
  • Structural Engineering (AREA)
  • Soil Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Paleontology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Biochemistry (AREA)
  • Civil Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14845600A 1999-09-07 2000-09-07 Combined vaccine compositions IL148456A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9921146A GB9921146D0 (en) 1999-09-07 1999-09-07 Novel composition
PCT/EP2000/008784 WO2001017551A2 (en) 1999-09-07 2000-09-07 Combined vaccine compositions

Publications (1)

Publication Number Publication Date
IL148456A0 true IL148456A0 (en) 2002-09-12

Family

ID=10860520

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15810700A IL158107A0 (en) 1999-09-07 2000-09-07 Human papillomaviruses vaccine
IL14845600A IL148456A0 (en) 1999-09-07 2000-09-07 Combined vaccine compositions
IL158107A IL158107A (en) 1999-09-07 2003-09-25 Vaccine for human papillomavirus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15810700A IL158107A0 (en) 1999-09-07 2000-09-07 Human papillomaviruses vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158107A IL158107A (en) 1999-09-07 2003-09-25 Vaccine for human papillomavirus

Country Status (33)

Country Link
US (3) US6936255B1 (de)
EP (3) EP1769806A3 (de)
JP (2) JP4689910B2 (de)
KR (2) KR100557665B1 (de)
CN (2) CN100389824C (de)
AR (1) AR025502A1 (de)
AT (2) ATE321569T1 (de)
AU (1) AU766494B2 (de)
BR (1) BR0014171A (de)
CA (2) CA2443214C (de)
CO (1) CO5280045A1 (de)
CY (2) CY1107457T1 (de)
CZ (2) CZ302811B6 (de)
DE (2) DE60027029T2 (de)
DK (2) DK1210113T3 (de)
ES (2) ES2253636T3 (de)
GB (1) GB9921146D0 (de)
GC (1) GC0000201A (de)
HK (2) HK1064958A1 (de)
HU (2) HU229099B1 (de)
IL (3) IL158107A0 (de)
MX (1) MXPA02002484A (de)
MY (2) MY130084A (de)
NO (3) NO332800B1 (de)
NZ (2) NZ527560A (de)
PL (2) PL201767B1 (de)
PT (1) PT1210113E (de)
SG (1) SG110072A1 (de)
SI (2) SI1210113T1 (de)
TR (1) TR200200607T2 (de)
TW (1) TWI258374B (de)
WO (1) WO2001017551A2 (de)
ZA (2) ZA200306402B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
BR9910643A (pt) 1998-05-22 2001-10-30 Loeb Health Res Inst At The Ot Processos e produtos para a indução de imunidadede mucosa
PL201482B1 (pl) * 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ATE354662T1 (de) * 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7407807B2 (en) † 2002-05-17 2008-08-05 University Of Cape Town Chimaeric human papillomavirus 16 I1 virus like particles and a method for preparing the particles
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP2402026A3 (de) 2002-09-13 2012-04-18 Intercell AG Verfahren zum Isolieren von Hepatitis-C-Virus-Peptiden
EP2241325B1 (de) 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Verwendung von CPG Oligonukleotide zur Behandlung von Hepatitis C Virus Infektion
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20060251676A1 (en) * 2002-12-20 2006-11-09 Gary Dubin Hpv-16 and-18 l1 vlp vaccine
SI1572233T1 (sl) * 2002-12-20 2011-07-29 Glaxosmithkline Biolog Sa Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
ES2562456T3 (es) * 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
CN101146551A (zh) * 2005-02-16 2008-03-19 诺华疫苗和诊断公司 含有磷酸铝和3d-mpl的佐剂组合物
JP4182074B2 (ja) 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
EP1863529A1 (de) * 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Neue zusammensetzung
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
AR053715A1 (es) * 2005-04-26 2007-05-16 Glaxosmithkline Biolog Sa Vacuna multivalente de vph
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
PL2275132T3 (pl) 2005-12-29 2021-09-13 Boehringer Ingelheim Animal Health USA Inc. Multiwalentne immunogenne kompozycje PCV2 i sposoby ich wytwarzania
CN109125721A (zh) 2005-12-29 2019-01-04 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2免疫原性组合物用于减轻猪临床症状的用途
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
HUE037808T2 (hu) 2006-09-26 2018-09-28 Infectious Disease Res Inst Szintetikus adalékanyagot tartalmazó vakcina kompozíció
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
WO2008112125A1 (en) 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
KR20150090285A (ko) 2007-06-26 2015-08-05 고에키자이단호진 휴먼 사이언스 신코우자이단 고리스크군 인간 파필로마 바이러스에 대한 교차성 중화 항체를 유도하는 백신 항원
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
PT2318042E (pt) * 2008-07-31 2014-11-05 Glaxosmithkline Biolog Sa Vacina contra hpv
WO2010135749A1 (en) 2009-05-22 2010-11-25 Genocea Biosciences Inc. Herpes simplex virus type2: compositions and methods for eliciting an immune response
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
US20120087937A1 (en) * 2009-06-25 2012-04-12 Brigitte Desiree Alberte Colau Novel compositions
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
EP2575878B1 (de) * 2010-05-28 2018-06-13 Zoetis Belgium S.A. Impstoffe mit cholesterin und cpg als einzige adjuvans-träger moleküle
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
CN103154737B (zh) * 2010-08-27 2015-07-15 英特维特国际股份有限公司 疫苗制剂的效价测试
CN102008721A (zh) * 2010-11-16 2011-04-13 浙江大学 一种hpv多肽/dc混合疫苗及其制备
EP2643014A4 (de) 2010-11-24 2015-11-11 Genocea Biosciences Inc Impfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
CA2834618C (en) * 2011-06-24 2020-11-03 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CA2843854A1 (en) * 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EP3711768A1 (de) 2013-04-18 2020-09-23 Immune Design Corp. Gla-monotherapie zur verwendung in der krebsbehandlung
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
US10953108B2 (en) 2016-08-01 2021-03-23 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
CN110576034B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复方法
CN110652980B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复剂
EP4058581A1 (de) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i-agonist und adjuvans-formulierung zur tumorbehandlung
CN114681602B (zh) * 2020-12-25 2023-12-01 中国食品药品检定研究院 一种双价人乳头瘤病毒疫苗

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ATE332973T1 (de) * 1991-07-19 2006-08-15 Univ Queensland Polynukleotidabschnitt des hpv16-genoms
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
KR100310510B1 (ko) * 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
EP0812358A1 (de) * 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptide verwendbar als immunotherapeutischen mitteln und verfahren zur bereitung von polypeptiden
US6172192B1 (en) * 1996-01-26 2001-01-09 Innogenetics N.V. Toxoplasma gondii antigen Tg20
HUP0001991A3 (en) * 1996-02-09 2003-08-28 Univ Liege Vaccines against varicella zoster virus gene 63 product
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
CA2324289C (en) * 1998-03-09 2010-07-13 Smithkline Beecham Biologicals S.A. Combined vaccine compositions
US6500284B1 (en) 1998-06-10 2002-12-31 Suraltech, Inc. Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
DE60040727D1 (de) * 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
IL158107A (en) 2008-11-03
BR0014171A (pt) 2002-05-21
NZ527560A (en) 2004-12-24
CA2443214C (en) 2006-03-21
HUP0202804A2 (hu) 2002-12-28
AU7775100A (en) 2001-04-10
ES2253636T3 (es) 2006-06-01
TR200200607T2 (tr) 2002-06-21
PL201264B1 (pl) 2009-03-31
PL201767B1 (pl) 2009-05-29
PL354039A1 (en) 2003-12-15
NO20021116L (no) 2002-04-30
HU228687B1 (en) 2013-05-28
ZA200306402B (en) 2004-08-02
GC0000201A (en) 2006-03-29
HK1048435B (zh) 2007-01-05
DK1210113T3 (da) 2006-07-03
US20040126394A1 (en) 2004-07-01
EP1410805B1 (de) 2005-12-14
KR100594668B1 (ko) 2006-06-30
SG110072A1 (en) 2005-04-28
KR20020027630A (ko) 2002-04-13
CA2384064A1 (en) 2001-03-15
NO2012016I1 (no) 2012-10-15
SI1210113T1 (sl) 2006-08-31
US7101560B2 (en) 2006-09-05
NO20033715D0 (no) 2003-08-21
JP2003508495A (ja) 2003-03-04
NO331825B1 (no) 2012-04-10
ATE312624T1 (de) 2005-12-15
US6936255B1 (en) 2005-08-30
HK1064958A1 (en) 2005-02-08
KR100557665B1 (ko) 2006-03-06
DE60027029T2 (de) 2006-10-19
NO332800B1 (no) 2013-01-14
NO20021116D0 (no) 2002-03-06
CN1325117C (zh) 2007-07-11
CY1106090T1 (el) 2011-06-08
CY1107457T1 (el) 2012-12-19
PT1210113E (pt) 2006-07-31
HU0303215D0 (en) 2003-11-28
CN1618465A (zh) 2005-05-25
HUP0202804A3 (en) 2004-08-30
SI1410805T1 (sl) 2006-04-30
GB9921146D0 (en) 1999-11-10
EP1410805A1 (de) 2004-04-21
JP4689910B2 (ja) 2011-06-01
AR025502A1 (es) 2002-11-27
EP1769806A3 (de) 2007-10-24
AU766494B2 (en) 2003-10-16
TWI258374B (en) 2006-07-21
US7220551B2 (en) 2007-05-22
MY130084A (en) 2007-05-31
DE60027029D1 (de) 2006-05-18
ES2261243T3 (es) 2006-11-16
CN100389824C (zh) 2008-05-28
CZ302811B6 (cs) 2011-11-23
NO2012016I2 (no) 2012-10-08
CN1387443A (zh) 2002-12-25
HU229099B1 (en) 2013-07-29
JP2004067696A (ja) 2004-03-04
HUP0303215A3 (en) 2008-04-28
MXPA02002484A (es) 2002-08-28
US20060280756A1 (en) 2006-12-14
TW200408405A (en) 2004-06-01
ATE321569T1 (de) 2006-04-15
WO2001017551A3 (en) 2001-09-27
EP1769806A2 (de) 2007-04-04
DK1410805T3 (da) 2006-04-18
MY142842A (en) 2011-01-14
ZA200201810B (en) 2004-05-26
KR20030087081A (ko) 2003-11-12
HK1048435A1 (en) 2003-04-04
DE60024893T2 (de) 2006-07-06
DE60024893D1 (de) 2006-01-19
CZ2002843A3 (cs) 2002-08-14
CA2384064C (en) 2010-06-01
CO5280045A1 (es) 2003-05-30
EP1210113B1 (de) 2006-03-29
NZ517621A (en) 2003-09-26
CA2443214A1 (en) 2001-03-15
IL158107A0 (en) 2004-03-28
WO2001017551A2 (en) 2001-03-15
NO20033715L (no) 2002-04-30
EP1210113A2 (de) 2002-06-05

Similar Documents

Publication Publication Date Title
HK1048435A1 (en) Combined vaccine compositions
HK1105581A1 (en) Vaccine composition
HUP0101047A3 (en) Combined vaccine compositions
HUP0301413A3 (en) Vaccine compositions
IL137999A0 (en) Vaccine compositions
HUP0302117A3 (en) Vaccine composition
GB0020089D0 (en) Vaccine Composition
GB9910812D0 (en) Vaccine composition
GB9904049D0 (en) Rapidly-soluble compositions
GB9921347D0 (en) Novel immunogenic compositions
AU1101701A (en) Vaccine compositions
GB9903924D0 (en) Cosmectic compositions
GB9904931D0 (en) Compositions
GB9929434D0 (en) Novel vaccine composition
GB9911823D0 (en) New vaccine formulations
GB9930458D0 (en) Vaccine compositions
GB9930461D0 (en) Vaccine compositions
GB9930455D0 (en) Vaccine compositions
GB9930456D0 (en) Vaccine compositions
GB9930457D0 (en) Vaccine compositions
GB9930460D0 (en) Vaccine compositions
GB9930459D0 (en) Vaccine compositions
GB9906694D0 (en) Vaccine composition
GB9906696D0 (en) Vaccine composition
GB0006770D0 (en) Vaccine composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees